drugset / Trial / NCT00492167

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

NCT00492167

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Beta-glucan may stimulate the immune system and stop tumor cells from growing. Monoclonal antibodies, such as 3F8, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving beta-glucan together with monoclonal antibody 3F8 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan when given together with monoclonal antibody 3F8 in treating patients with metastatic neuroblastoma.

Timeline

Start
2005-09-09
Primary completion
2022-03-04
Completion
2022-03-04

Drugs

EvaluationDrugModalityDoseRoute
Subject 3F8 Monoclonal antibody 10 mg/m2 Intravenous
Subject beta-glucan Other / unclassified 10 mg/kg Oral
Subject beta-glucan Other / unclassified 120 mg/kg Oral
Subject beta-glucan Other / unclassified 200 mg/kg Oral

Indications